目的:本研究的目的是评估经动脉基准标记物植入用于射波刀放射治疗局部晚期胰腺癌的安全性和可行性。
方法:对15例胰腺癌患者进行经动脉标记物植入。栓塞铂线圈被植入作为癌症边缘20毫米内的基准标记,并且优选地在3mm内。植入的技术成功被定义为在目标肿瘤的20mm内植入至少一个基准标记。使用射波刀系统进行照射。
结果:对于15例患者中的14例,成功进行了经动脉植入,14个病人中的13个,跟踪标记被植入在距离癌症3毫米的范围内.在两名患者中观察到跟踪不稳定,但14例患者均完成了放疗。未观察到由植入程序引起的主要并发症。照射后的中位总生存期为13.8个月,1年和2年生存率分别为62.9%和32.3%,分别。
结论:胰腺癌的经动脉基准标记物植入可以安全地进行跟踪,这将是经皮基准标记物植入的一种有价值的替代方法。
OBJECTIVE: The purpose of this study was to evaluate the safety and feasibility of transarterial fiducial marker implantation for CyberKnife radiotherapy to treat locally advanced pancreatic cancer.
METHODS: Fifteen pancreatic cancer patients were enrolled for transarterial marker implantation. Embolization platinum coils were implanted as a fiducial marker within 20 mm of the cancer edge, and preferably within 3 mm. The technical success of the implantation was defined as implantation of at least one fiducial marker within 20 mm of the target tumor. Irradiation was performed using the CyberKnife system.
RESULTS: For 14 of 15 patients, transarterial implantation was successfully performed, and for 13 of 14 patients, the tracking marker was implanted within 3 mm of the cancer. Tracking instability was observed in two patients, but irradiation was accomplished in all 14 patients. No major complications caused by the implantation procedure were observed. The median overall survival after irradiation was 13.8 months, and the 1- and 2-years survival rates were 62.9% and 32.3%, respectively.
CONCLUSIONS: Transarterial fiducial marker implantation for pancreatic cancer can be safely performed for tracking, and it will be a valuable alternative approach to percutaneous fiducial marker implantation.